What is the worldwide distribution and areas of highest prevalence of Echinococcus granulosus sensu lato?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Worldwide Distribution of Echinococcus granulosus sensu lato

E. granulosus sensu lato has a worldwide distribution, with the highest prevalence documented in Eastern Europe, the Middle East, North Africa, western China, central Asia, the Mediterranean region, eastern Africa, and parts of South America. 1

Global Distribution Pattern

The parasite is found on all continents except Antarctica 2. According to the most recent 2025 UK guidelines, E. granulosus presents worldwide, with cases in the UK most commonly occurring in migrants from Eastern Europe, Middle East, and North Africa 1.

Regional Prevalence Patterns

High Prevalence Regions

The areas with documented high disease burden include:

  • Asia: Western China and central Asia show particularly high prevalence 3. Recent systematic reviews confirm E. granulosus sensu stricto (G1-G3) is the most widely distributed genotype across five major continents 4

  • Middle East and Mediterranean: These regions consistently demonstrate elevated infection rates, with major space-time clusters identified in East/Central Asia and the Middle East 5

  • Eastern Europe: This region shows significant prevalence, particularly in countries like Russia, Kazakhstan, Kyrgyzstan, and Uzbekistan 6

  • Africa: Eastern Africa and North Africa are endemic areas, with documented prevalence in goats reaching 13.27% in some African regions 6

  • South America: Parts of South America show high prevalence, with meta-analysis revealing the highest pooled molecular prevalence of canine echinococcosis at 66.03% 7. Animal prevalence in goats ranges from 6.16%-10.85% 6

Ecological and Environmental Factors

Recent ecological niche modeling demonstrates that annual mean temperature (54.8% contribution) and elevation (23.5%) are the dominant predictors of E. granulosus distribution, with highest suitability under moderate temperature and precipitation conditions 5. The parasite shows a unimodal response to climatic gradients, explaining its geographic clustering in specific regions.

Clinical Context

The worldwide distribution creates significant public health challenges, as the disease poses a biological threat with increasing numbers of infected people globally 6. In the Russian Federation alone, the 2023 incidence was 494 cases (0.34 per 100,000 people) 6.

Important Caveat

While E. granulosus has worldwide distribution, low prevalence settings such as high-income countries often face challenges related to low disease awareness, leading to misdiagnosis and inappropriate treatments 8. This is particularly problematic as 134 out of 155 patients undergoing surgical treatment were initially misdiagnosed with either malignant or benign tumors 9.

Related Questions

What is the preferred oral medication for treating an infected hepatic hydatid cyst?
How should echinococcosis be prevented and managed, including recommended drug therapy and indications for surgery or percutaneous PAIR intervention?
How should cystic echinococcosis be diagnosed and managed in patients who have lived in or traveled to western China, central Asia, the Middle East, the Mediterranean region, eastern Africa, or parts of South America and present with hepatic, pulmonary, or other organ cystic lesions?
What Echinococcus species and genotypes are responsible for human cystic echinococcosis?
In hepatic hydatid cysts, under what circumstances is medical management and observation indicated?
What are the possible causes of left gluteal muscle pain and what is the appropriate next step in management?
What are the indications, dosing regimens, and advantages of isosorbide mononitrate compared with isosorbide dinitrate for chronic angina and heart failure management?
What is the PALM (Pcrit, Arousal threshold, Loop gain, Muscle responsiveness) critical classification of obstructive sleep apnea?
How should cystic echinococcosis be diagnosed and managed in patients who have lived in or traveled to western China, central Asia, the Middle East, the Mediterranean region, eastern Africa, or parts of South America and present with hepatic, pulmonary, or other organ cystic lesions?
What is the recommended limit of digital screen exposure for a 7‑month‑old infant?
What is the recommended diagnostic work‑up and treatment plan for a patient with suspected alveolar echinococcosis presenting with hepatic cystic lesions after living or traveling in endemic regions such as western China, central Asia, the Alpine, sub‑Arctic or Arctic areas?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.